Pemafibrate

2 papers7 findings

A preprint reports that pemafibrate improves airflow obstruction in long-term smoke-exposed mice and increases autophagy while reducing senescence in human bronchial epithelial cells exposed to cigarette smoke extract. It also reports slower FEV1.0 decline in humans versus bezafibrate or fenofibrate. All four findings come from one lab, without independent replication, and name Kowa Company as funder.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country
12 trials, 2 with no results posted

Funder: Kowa Company
1 of 12 trials sponsored by its developers

Animals1

Outcomes

FEV1.0 decline

downin humans1

1 study

Pemafibrate decreases FEV1.0 decline in humans.
Humanscompared with bezafibrate or fenofibrate
Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease
medRxiv2 Sep 2026Preprint

Airflow obstruction

upin mice1

1 study

Pemafibrate improves airflow obstruction in mice.
Animalslong-term CS-exposed
Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease
medRxiv2 Sep 2026Preprint

Autophagy

upin human cells1

1 study

Pemafibrate activates autophagy in human cells.
Cellscigarette smoke extract exposurebronchial epithelium
Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease
medRxiv2 Sep 2026Preprint

Trials

In trials

Hypercholesterolemia
Phase 4Recruiting2 trials
Dyslipidemias
Phase 3Completed4 trials
Diabetic retinopathy
Phase 3Terminated1 trial
Hyperlipidemias
Phase 3Completed1 trial
Biliary Liver Cirrhosis
Phase 2Completed2 trials
Non-alcoholic fatty liver disease
Phase 2Completed2 trials

Stopped

NCT03071692TerminatedDyslipidemias
The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
NCT03345901TerminatedDiabetic retinopathy
recruitment for the substudy did not meet the goals